A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.

Janux Therapeutics has commenced Phase Ib expansion trials with JANX007 in the first-in-human ENGAGER-PSMA-01 clinical trial.

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI ...

In the face of growing global healthcare challenges, breast cancer remains a key area of ​​concern due to its increasing prevalence worldwide. The Global Breast Cancer Therape ...

Definition: A labour market is the place where workers and employees interact with each other. In the labour market, employers compete to hire the best, and the workers compete for the best satisfying ...